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Abstract
Background: In HIV-infected children, viral diversity tends to increase with age in the absence of antiretroviral treatment
(ART). We measured HIV diversity in African children (ages 6–36 months) enrolled in a randomized clinical trial comparing
two ART regimens (Cohort I of the P1060 trial). Children in this cohort were exposed to single dose nevirapine (sdNVP) at
birth.
Methods: HIV diversity was measured retrospectively using a high resolution melting (HRM) diversity assay. Samples were
obtained from 139 children at the enrollment visit prior to ART initiation. Six regions of the HIV genome were analyzed: two
in gag, one in pol, and three in env. A single numeric HRM score that reflects HIV diversity was generated for each region;
composite HRM scores were also calculated (mean and median for all six regions).
Results: In multivariable median regression models using backwards selection that started with demographic and clinical
variables, older age was associated with higher HRM scores (higher HIV diversity) in pol (P=0.005) and with higher mean
(P=0.014) and median (P,0.001) HRM scores. In multivariable models adjusted for age, pre-treatment HIV viral load, pre-
treatment CD4%, and randomized treatment regimen, higher HRM scores in pol were associated with shorter time to
virologic suppression (P=0.016) and longer time to study endpoints (virologic failure [VF], VF/death, and VF/off study
treatment; P,0.001 for all measures).
Conclusions: In this cohort of sdNVP-exposed, ART-naı ¨ve African children, higher levels of HIV diversity in the HIV pol region
prior to ART initiation were associated with better treatment outcomes.
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Introduction
Mother-to-child transmission (MTCT) of HIV can occur in
utero, at the time of delivery, or during breastfeeding [1]. Most
HIV-infected infants have relatively homogeneous viral popula-
tions that tend to diversify over time [2–5]. This is consistent with
studies in adults that find that HIV infection is typically initiated
by only one or a few HIV variants [6]. HIV diversification is
driven by its large viral population size, rapid viral turnover, error-
prone replication, and frequent genetic recombination [6].
Selective pressures, such as antiretroviral (ARV) drug use and
the immune response, can further affect viral diversification [5,7–
9].
Previous studies examining the relationship between HIV
diversity and disease progression have found conflicting results.
In adults, high HIV diversity in the env region has been associated
with both rapid [10,11] and slow [12,13] disease progression. In
infants, some studies found an association between higher
env diversity and slower disease progression [13–15] while
others found no association between HIV diversity and disease
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e81213progression [16]. Most studies of HIV diversity have used methods
based on the comparison of sequences from individual HIV
variants, which is time consuming and costly. This often limits the
number of individuals, samples, and genomic regions that can be
analyzed. The small sample volumes that are typically collected
and stored in pediatric studies may be another factor limiting the
analyses of HIV diversity in infants and children. For example, the
studies described above included fewer than 20 children and were
restricted to analysis of the env region [13–16].
We developed an assay based on high resolution melting (HRM)
technology that can be used to quantify the genetic diversity of
HIV populations without sequencing [17]. The level of viral
diversity in each region of the HIV genome is expressed as a single
numeric HRM score [17]. These scores are highly correlated with
sequence-based diversity measures obtained through traditional
sequencing of HIV-derived clones [17] and next generation
sequencing of HIV populations [18]. In a previous study of 31
HIV-infected infants in Uganda, we found that higher HRM
scores in the gag and pol regions were associated with older age and
decreased 5-year survival [4]. We also found an association
between higher HRM scores (in gag, pol, and env regions) and older
age in a separate cohort of 76 Ugandan children aged 0.6–12.4
years [5]. In addition, prolonged exposure of HIV-infected
children to a non-suppressive ARV drug regimen was associated
with a significant reduction in the diversity of the viral population
(i.e., genetic bottlenecking) [5].
In this report, we used the HRM diversity assay to evaluate the
relationship between HIV diversity in gag, pol, and env and response
to ARV treatment (ART) among 139 African children in the
P1060 multi-national, randomized, clinical trial (NCT00307151)
[19].
Methods
Ethics statement
Written informed consent was obtained from the parents or
legal guardians of all children enrolled in the study. The P1060
trial was approved by the Ministries of Health and the ethics
review committees at the local study sites: University of Kwazulu-
Natal Biomedical Research Ethics Administration; University of
the Witwatersrand Ethics Committee; Stellenbosch University;
Medical Research Council of Zimbabwe; University of Zambia
Research Ethics Committee; Malawi National Health Sciences
Research Committee; Uganda National Council for Science and
Technology HIV/AIDS Research Committee; Kilimanjaro
Christian Medical College Institutional Ethics Committee; and
the Medicines Control Council. The P1060 trial was also
approved by the institutional review boards of the participating
institutions in the United States: University of Alabama at
Birmingham; Johns Hopkins University School of Medicine;
University of North Carolina at Chapel Hill; and Duke University
Health System [19]. The laboratory studies described in this
report were approved by the institutional review board at Johns
Hopkins University School of Medicine.
Study cohort
Cohort I of the P1060 trial enrolled 164 children (ages 6–36
months) at nine sites in six African countries (four sites in South
Africa and one each in Zimbabwe, Zambia, Malawi, Uganda, and
Tanzania) [19]. Children in Cohort I had been exposed to single
dose nevirapine (sdNVP) at the time of birth (159 received sdNVP
and 5 were exposed through maternal sdNVP dosing). Maternal
use of ARV drugs other than non-nucleoside reverse transcriptase
inhibitors during pregnancy was permitted. All children met the
World Health Organization (WHO) criteria for ART. Children
were randomized to receive an initial regimen of lamivudine (3TC)
and zidovudine (ZDV) with either nevirapine (NVP) or ritonavir-
boosted lopinavir (LPV/r). The primary study endpoints were
virologic failure or discontinuation of the NVP or LPV/r
component of the ART regimen by week 24 [19].
Laboratory methods
CD4 cell count, CD4%, and HIV viral load were measured in
real time during the P1060 trial [19]. HIV genotyping was
performed retrospectively using the ViroSeq HIV Genotyping
System (Celera, Alameda, CA) [19]. HIV RNA or DNA
remaining from genotyping was used to prepare template DNA
for HRM analysis [20]. Six regions of the HIV genome were
analyzed: two in gag (GAG1, GAG2), one in pol (POL), and three
in env (ENV1, ENV2, ENV3). The HRM diversity assay was
performed as previously described [20]. DNA corresponding to
each region of interest was amplified by a nested polymerase chain
reaction (PCR) in the presence of an intercalating duplex-
dependent fluorescent dye. The DNA samples were then melted
using a LightScanner instrument (Model HR 96, BioFire
Diagnostics Inc., Salt Lake City, UT), and melting was monitored
by the decline in fluorescence due to the release of the dye. HRM
scores were calculated using an automated software tool (DivMelt,
version 1.0.2) [21]; composite scores (mean and median across the
six regions) were also calculated. These scores reflect the range of
temperatures over which DNA melting occurred.
Statistical methods
Fisher’s exact and Wilcoxon rank-sum tests were used to
compare the characteristics of participants with and without HRM
results for categorical and continuous variables, respectively.
Spearman correlations for continuous variables and Kruskal-
Wallis tests for categorical variables were used to determine
whether HRM scores were associated with characteristics at study
enrollment. Median regression was used in multivariable analyses
because of outliers in the HRM scores, which could over-influence
results using linear regression techniques. Multivariable analysis
was performed using backwards stepwise median regression
starting with any variables that were significant in the univariate
analysis at the P,0.10 level. The least significant variable was
sequentially dropped from the model until any remaining variables
were significant at the P,0.05 level.
Cox proportional hazards regression was used to assess whether
HRM scores were associated with time to virologic suppression,
virologic failure, virologic failure or death, and virologic failure or
discontinuation of the randomized NVP or LPV/r component of
the study regimen. Virologic failure was defined previously as
either not achieving virologic suppression within 24 weeks or
rebounding after 24 weeks [19]. Time to study endpoints was used
for analyses (rather than dichotomous endpoint outcomes) since
the duration of follow-up varied among the study participants (2–
120 weeks); this approach increased the power for detecting
differences. Models were stratified by age group (,12 months vs.
$12 months) and then adjusted for age within each group. In
addition, because pre-treatment viral load and CD4% were
associated with time to study endpoints in the primary analyses of
the P1060 trial [19], models were also adjusted for these factors as
well as randomized study treatment arm.
We also analyzed the relationship between age and treatment
adherence, which was documented in the P1060 trial as missed
doses at the 2, 4, 8, 12, 16, and 24 week visits. Perfect adherence at
each study visit was defined as the caregiver reporting no missed
doses of study treatment in the three days prior to the visit.
HIV Diversity and Treatment Outcome
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distribution of the participants with and without perfect adherence
at each study visit.
Results
Study participants
The HRM diversity assay was performed using samples
collected prior to initiation of ART (pre-treatment samples).
Samples were available for analysis from 139 (84.8%) of the 164
children enrolled in Cohort I of the P1060 trial (Figure 1, Table 1).
The 139 children included in the study were more likely to be
from South Africa (P,0.001), have no history of breastfeeding
(P=0.015), and have more advanced HIV disease as assessed by
WHO stage (P=0.047). Pre-treatment HIV viral loads were
.24,400 copies/mL for all 164 children in Cohort I of P1060. No
statistically significant differences were observed for CD4 cell
count, CD4%, or HIV viral load among the children who were vs.
were not included in the study. There were also no significant
differences between the groups in the proportion of children who
reached study endpoints (data not shown).
Association of HIV diversity with demographic and
clinical characteristics
We evaluated the association between pre-treatment HRM
scores and demographic and clinical characteristics of the study
participants. Results obtained for continuous and categorical
variables are shown in Tables 2 and 3, respectively. Analyses were
performed using the HRM score obtained for each region of the
HIV genome and for the mean and median of the six HRM
scores. In univariate tests, several variables were associated with
higher HRM scores (Tables 2 and 3). In multivariable median
regression models using backwards selection, only age and
maternal ARV drug use remained associated with any HRM
scores. Older age was associated with higher POL HRM scores
(P=0.005) and also with higher mean (P=0.014) and median
(P,0.001) HRM scores. No history of maternal ARV drug use
was associated with higher GAG2 HRM scores (P=0.002).
Association of HIV diversity and clinical outcome
Ninety-four (68%) of the 139 children analyzed in this
report achieved virologic suppression on ART, defined as two
consecutive HIV viral load values ,400 copies/mL after initiation
of ART. In these analyses, statistical models were adjusted for
study treatment regimen, age (years), CD4%, and HIV viral load
(see Methods). Higher POL HRM scores were associated with a
shorter time to virologic suppression (hazard ratio [HR]: 1.57,
95% confidence intervals [CI]: 1.09–2.26, P=0.016, Table 4).
Higher GAG1 and median composite scores were also significantly
associated with shorter time to virologic suppression (Table 4).
We next assessed the association of HRM scores with time to
study endpoints (Table 4). Among the 139 children, 19 experi-
enced virologic failure, one experienced virologic failure and
discontinued the study ART regimen at the same study visit, five
died, and 22 discontinued the study ART regimen without first
experiencing virologic failure. ENV1, ENV3, and GAG2 HRM
scores were not significantly associated with time to any endpoint.
We found that higher POL HRM scores were associated with a
longer time to all three study endpoints (P,0.001 for all three
endpoints). In addition, higher GAG1 (P=0.009), mean
(P=0.005), and median (P=0.002) HRM scores were associated
with longer time to the composite endpoint of study treatment
discontinuation or virologic failure, and higher ENV2 (P=0.037)
HRM scores were associated with shorter time to virologic failure.
The models reported in Table 4 assume a linear relationship
between HRM scores and the hazard for study endpoints. We also
evaluated the association between HRM scores and time to study
endpoints using a dichotomous measure (above the median HRM
score vs. at or below the median HRM score for each region).
Similar associations were observed for POL, mean, and median
HRM scores using both continuous and dichotomous measures.
Higher (above the median) POL (HR: 0.30, 95% CI: 0.15–0.61,
P=0.001, Figure 2), mean (HR: 0.44, 95% CI: 0.23–0.85,
P=0.014), and median (HR: 0.28, 95% CI: 0.13–0.57, P=0.001)
HRM scores were all associated with longer time to the composite
endpoint of study treatment discontinuation or virologic failure.
Higher POL HRM scores were also associated with a longer time
Figure 1. Study cohort. The high resolution melting (HRM) diversity assay was used to analyze samples from 139 (84.8%) of the 164 children
enrolled in Cohort I of the P1060 trial. The 139 children had HIV genotyping results at study enrollment (prior to initiation of antiretroviral treatment)
and had sufficient HIV RNA or DNA remaining after genotyping for analysis using the HRM diversity assay.
doi:10.1371/journal.pone.0081213.g001
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and the composite endpoint of virologic failure or death (HR:
0.30, 95% CI: 0.12–0.74, P=0.009). Higher ENV2 HRM scores
also remained associated with a shorter time to virologic failure
(HR: 3.75, 95% CI: 1.45–9.69, P=0.006). In contrast, we did not
observe an association between GAG1 HRM scores and any study
outcome using dichotomous measures.
We considered whether the observed associations between
higher pol diversity and better treatment outcomes may have
reflected better adherence to treatment regimens among older
children (who also had higher viral diversity). In the P1060 trial,
treatment adherence was assessed by maternal report of missed
doses at study visits 2 to 24 weeks after treatment initiation. Of the
139 children included in this study, over 92% did not have any
report of missed doses. The percentage of participants with no
missed doses ranged from 93.0% at week 8 (n=114) to 98.4% at
week 4 (n=128). Furthermore, there was no indication that
adherence was better among older children.
Discussion
In this study, we identified a novel factor associated with clinical
outcome on ART: a higher level of HIV diversity in the pol region
prior to ART initiation. This association remained statistically
significant in multivariate models adjusted for age, pre-treatment
HIV viral load, pre-treatment CD4%, and ART regimen. The
association of higher pol diversity with improved clinical outcomes
was seen with a variety of outcome measures including: shorter
time to virologic suppression after ART initiation, longer time to
virologic failure, and longer time to the composite outcomes of
virologic failure with either death or discontinuation of the study
ART regimen. In this cohort, the definition of virologic failure
took into account both initial viral suppression on ART and viral
rebound (see Methods). The association between higher pol
diversity and better clinical outcomes was observed for all study
endpoints examined and when both continuous and dichotomous
(above or below median group levels) diversity measures were
used. Similar associations were seen for some of these comparisons
when the analysis was performed using composite diversity
measures (mean or median of measures from regions in HIV
gag, pol, and env).
We also observed associations between HIV diversity measures
in individual env or gag regions and study outcomes, but those
findings were less consistent. For example, higher diversity in the
ENV2 region was associated with shorter time to virologic failure
(a worse study outcome). However, this association held for only
one of the outcome measures. Higher diversity in the GAG1
region was associated with shorter time to virologic suppression
and with longer time to the composite endpoint of viral failure or
treatment discontinuation (better study outcomes). However, other
regions of env (ENV1 and ENV3) and gag (GAG2) were not
associated with any study outcome.
Results in this study are different from those of an observational
cohort of Ugandan children on ART [5]. In that study, higher
levels of env and gag diversity were associated with ART failure,
while pol diversity was not. There are many differences between
that study and this report that may account for the differences in
our findings. This report included 139 children (vs. 76), children
from four countries (vs. one country), children who were mostly
infected with HIV subtype C (vs. A and D), children ages 6 to 36
months (vs. ages 6 months to 12.4 years), children who
discontinued the ART regimen if they experienced viral failure
(vs. continuing ART despite a lack of viral suppression), a variety
of study endpoints (vs. only viral rebound), and was performed in
the context of a randomized, clinical trial (vs. an observational
cohort). Therefore, while the results of both studies are valid, we
feel that the results from this study may be of more general
relevance.
In this study of children ages 6–36 months, older age was
significantly associated with higher diversity in the pol region. An
association between higher levels of HIV diversity and older age
was also observed in our previous studies of Ugandan infants and
children [4,5]. In these pediatric studies where children were
known or likely to have been infected by MTCT, age serves as a
surrogate for duration of HIV infection. In both children and
Table 1. Cohort I baseline characteristics overall and by
inclusion in the analysis of HIV diversity.
Included in the study
Total Yes No
Characteristic (N=164) (N=139) (N=25) P value
Country S Africa 136 (83%) 122 (88%) 14 (56%) ,0.001
a
Other 28 (17%) 17 (12%) 11 (44%)
Treatment NVP 82 (50%) 67 (48%) 15 (60%) 0.39
a
LPV/r 82 (50%) 72 (52%) 10 (40%)
Gender Male 77 (47%) 63 (45%) 14 (56%) 0.39
a
Female 87 (53%) 76 (55%) 11 (44%)
Age stratum 6 m to ,12 m 123 (75%) 102 (73%) 21 (84%) 0.32
a
$12 m 41 (25%) 37 (27%) 4 (16%)
Ever breast fed Yes 34 (21%) 24 (17%) 10 (40%) 0.015
a
No 130 (79%) 115 (83%) 15 (60%)
Maternal ARV
use
c
Yes 59 (36%) 48 (35%) 11 (44%) 0.37
a
No 105 (64%) 91 (65%) 14 (56%)
WHO stage Stage I/II 72 (44%) 56 (40%) 16 (64%) 0.047
a
Stage III/IV 92 (56%) 83 (60%) 9 (36%)
HIV viral load
(log10)
Mean (sd) 5.7 (0.3) 5.7 (0.3) 5.6 (0.4) 0.43
b
CD4 cell count Mean (sd) 1261 (751) 1214 (693) 1522 (991) 0.20
b
CD4% Mean (sd) 20 (8) 20 (8) 22 (8) 0.09
b
Any ARV
resistance
d
No 130 (86%) 119 (86%) 11 (85%) 1.00
a
Yes 22 (14%) 20 (14%) 2 (15%)
Not available 12 0 12
HIV subtype C 149 (97%) 134 (96%) 15 (100%) 1.00
a
Not C 5 (3%) 5 (4%) 0 (0%)
Not available 10 0 10
The table shows baseline demographic and clinical characteristics for children
who were enrolled in Cohort I of the P1060 study and were vs. were not
included in the analysis of HIV diversity (see Figure 1). P values ,0.05 are
bolded. Abbreviations: S Africa: South Africa; NVP: nevirapine; LPV/r: lopinavir/
ritonavir; m: months; WHO: World Health Organization; sd: standard deviation;
HIV RNA: expressed as log10 copies/mL; CD4 cell count: expressed as cells/mm
3;
CD4%: CD4 cell percentage; ARV: antiretroviral.
aFisher’s Exact Test.
bWilcoxon Test.
cMaternal ARV drug use during pregnancy was reported for 48 infants; 47
women had used zidovudine (three had also used lamivudine [3TC]) and 1 had
used 3TC and stavudine.
dTwenty of the 139 infants in this study had ARV resistance at study entry; 15
had resistance to nevirapine (NVP), two had resistance to didanosine (ddI), two
had resistance to NVP and ddI, and one had resistance to 3TC and emtricitabine.
doi:10.1371/journal.pone.0081213.t001
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shown to vary from person-to-person and in different regions of
the HIV genome [4,5,20].
It is not clear why a higher level of pol diversity would be
associated with more rapid virologic suppression or other
improved clinical outcomes on ART. Because older age was also
associated with higher pol diversity, we considered that older
children might have been more adherent to their study regimens
and that this may have explained the better treatment outcomes in
children with higher pol diversity. However, there was no
significant difference in treatment adherence among older vs.
younger children. Therefore, it was unlikely that the association
between higher pol diversity and better treatment outcomes was
the result of better adherence among older children. We also note
that the multivariate models used for the analysis were adjusted for
age, in addition to other factors.
We also considered whether HIV viral load, which may be
associated with viral diversity, could have confounded our results.
Previous studies examining the relationship between HIV diversity
and viral load found conflicting results. In adults, one study found
an association between higher env diversity and higher viral load
[22], while two other studies found an association between higher
gag diversity and higher viral load [23,24]. In the latter two studies,
there was no association between env diversity and viral load
[23,24]. In this study of HIV-infected children, there was no
association between viral load and diversity in gag or pol and a
borderline association in env (p=0.05). This is consistent with our
studies of Ugandan infants where we found no association between
viral load and gag or pol diversity [4,17]. Furthermore, the
association we observed between pol diversity and treatment
outcomes in this study was independent of HIV viral load.
In theory, higher viral diversity might reflect a more vigorous
immune response to HIV infection, resulting in faster or greater
viral diversification and evolution. The strength of the immune
response in HIV-infected infants might be influenced by the viral
adaptation that appears to occur in vertical HIV transmission
[25]. Viruses transmitted to infants may have already adapted to
the mother’s HLA alleles and immune responses. Since infants
share half of the mother’s HLA alleles and since most of the
antibodies present in early infant infection are maternally-derived,
the virus may be partially adapted to the infant’s immune system
at the time of transmission. In cases where the infant’s virus is not
Table 2. Correlation of HIV diversity and continuous demographic and clinical factors.
Variable GAG1 GAG2 POL ENV1 ENV2 ENV3 MEAN MED
Age (yrs) 0.15 0.22 0.25 0.27 0.16 0.30 0.33 0.35
(0.08) (0.010)( 0.004)( 0.001) (0.06) (,0.001)( ,0.001)( ,0.001)
HIV RNA (log10) 0.11 20.02 20.13 20.16 0.06 0.08 20.02 20.03
(0.19) (0.84) (0.14) (0.05) (0.52) (0.36) (0.86) (0.75)
CD4 cell count 20.06 20.17 20.15 20.07 20.08 20.16 20.22 20.23
(0.50) (0.045) (0.09) (0.44) (0.38) (0.07) (0.008)( 0.006)
CD4% 20.05 20.16 20.08 20.08 20.14 20.09 20.17 20.23
(0.58) (0.06) (0.35) (0.33) (0.10) (0.32) (0.048)( 0.006)
The table shows Spearman correlation coefficients (P values) based on ranks of continuous baseline demographic and clinical characteristics and HRM scores. CD4 and
HIV-1 RNA were obtained at time of study enrollment and age was obtained at the time of randomization. HRM scores were obtained for six regions of the HIV genome
(see Methods); analyses were also performed for the mean (MEAN) and median (MED) of all six HRM scores. P values ,0.05 are bolded. Abbreviations: yrs: years; HIV
RNA: expressed as log10 copies/mL; CD4 cell count: expressed as cells/mm
3; CD4%: CD4 cell percentage.
doi:10.1371/journal.pone.0081213.t002
Table 3. Association of HIV diversity with categorical demographic and clinical factors.
Variable GAG1 GAG2 POL ENV1 ENV2 ENV3 MEAN MED
Ever breast fed 0.65 0.23 0.23 0.82 0.91 0.45 0.68 0.92
Country
a 0.57 0.24 0.18 0.28 0.98 0.28 0.45 0.61
HIV subtype
b 0.46 0.36 0.08 0.52 0.40 0.27 0.98 0.93
Infant ZDV use 0.18 0.33 0.56 0.07 0.34 0.08 0.09 0.06
Any maternal ARV use 0.06 0.019 0.15 0.011 0.66 0.10 0.020 0.002
Any ARV resistance 0.42 0.06 0.12 0.33 0.033 0.14 0.10 0.09
Gender 0.93 0.16 0.76 0.73 0.11 0.89 0.59 0.76
Randomized treatment 0.88 0.73 0.32 0.74 0.76 0.78 0.94 0.69
WHO stage
c 0.84 0.87 0.49 0.68 0.61 0.45 0.69 0.52
The table shows the statistical significance from Kruskal-Wallis tests of the association of baseline categorical demographic and clinical characteristics and HIV diversity
scores. HRM scores were obtained for six regions of the HIV genome (see Methods); analyses were also performed for the mean (MEAN) and median (MED) of all six HRM
scores. P values ,0.05 are bolded. Abbreviations: ZDV: zidovudine; ARV: antiretroviral; WHO: World Health Organization.
aCountry: South Africa vs. other countries.
bSubtype C vs. other subtypes.
cWHO stage I/II vs. WHO stage III/IV.
doi:10.1371/journal.pone.0081213.t003
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which could help contain the virus in the setting of ART. Very few
studies have examined the relationship between HIV diversity and
the immune response to HIV infection. One study found that
HIV-infected infants with slower disease progression and higher
viral diversity also had increased seroreactivity against the V3 loop
of HIV [14]. We previously used the BED capture immunoassay
and an avidity assay to assess antibody maturation in adults with
HIV infection [26,27]. The BED assay measures the proportion of
IgG that is HIV-specific [28], while the avidity assay measures
how well anti-HIV antibodies bind target antigens [29]. Further
studies could use these assays to evaluate the relationship between
the immune response, HIV diversity, and treatment outcome in
the P1060 cohort. It should be noted, however, that the association
between HIV diversity and treatment outcome in this study was
most striking for the pol region. While antibodies that target
products of the HIV pol gene have been described [30–32], those
proteins are not primary targets of the humoral immune response
to HIV infection.
Alternatively, higher levels of pol diversity prior to ART
initiation may reflect properties of the viral strain, such as faster
replication. The presence of ARV drug resistance mutations is
often associated with reduced viral fitness [33,34]. In theory, since
high viral replication rates are one factor driving viral diversifi-
cation, the diversity of viral populations might be reduced if those
populations included resistant strains with reduced replication
capacity. In this study, we did not see an association between pre-
treatment ARV drug resistance and HIV diversity in multivariate
models. Those results were based on resistance testing using a
population-sequencing method that may not have detected
resistant variants present at low levels [35]. We did consider the
possibility that children who were previously exposed to NVP for
prevention of MTCT (PMTCT) may have developed NVP
resistance prior to enrollment in the P1060 trial, and that this
may have led to a reduction in viral diversity, persistence of low-
level NVP-resistant variants [36,37], and worse outcomes on
ART. We did not have sufficient statistical power to investigate
possible interactions between treatment regimen and diversity.
However, lower pol diversity was still associated with worse
outcomes after controlling for treatment arm and other measures
of HIV disease. Therefore, prior exposure to NVP for PMTCT
was not likely to be responsible for the lower pol diversity observed
in children with worse treatment outcomes.
Even though we did not see an association between ARV drug
resistance and HIV diversity, differences in viral replication
capacity could still explain why higher pol diversity was associated
with better treatment outcomes. Higher replication capacity is
associated with more rapid viral turnover, which could result in
faster viral suppression on ART [38], as well as more rapid HIV
diversification. Future studies could investigate whether differences
in viral replication capacity could explain the association of higher
HIV pol diversity with better treatment outcomes in this cohort.
Another finding in this study was the association of increased
GAG2 diversity among infants whose mothers did not have a
history of ARV drug use (other than sdNVP for PMTCT).
Maternally-administered ARV drugs are known to be transferred
to infants in utero and during breastfeeding [39–41] and can induce
ARV drug resistance in infants [42,43]. In settings where women
are receiving ARV drugs while breastfeeding (e.g., ART for their
own infection or a triple drug regimen for prevention of post-natal
HIV transmission), this might result in a decrease in the diversity
of the infant’s virus (i.e., genetic bottlenecking), similar to that
observed when children are maintained on non-suppressive ART
[5]. These mechanisms are not likely to be relevant in this study,
since most women in this cohort of P1060 did not breastfeed prior
to study enrollment (83%) or during study follow-up [19].
Table 4. Association of HIV diversity and time to virologic
suppression and study endpoints.
Region Outcome HR 95% CI P value
GAG1 Virologic suppression 1.24 1.00, 1.54 0.047
VF/off-treatment 0.59 0.39, 0.87 0.009
VF/death 0.61 0.38, 0.99 0.046
VF alone 0.62 0.37, 1.05 0.08
GAG2 Virologic suppression 1.20 1.00, 1.45 0.052
VF/off-treatment 0.69 0.47, 1.02 0.06
VF/death 0.75 0.50, 1.14 0.19
VF alone 0.76 0.49, 1.19 0.24
POL Virologic suppression 1.57 1.09, 2.26 0.016
VF/off-treatment 0.35 0.19, 0.62 ,0.001
VF/death 0.19 0.08, 0.43 ,0.001
VF alone 0.16 0.06, 0.41 ,0.001
ENV1 Virologic suppression 1.02 0.89, 1.17 0.79
VF/off-treatment 0.88 0.59, 1.33 0.55
VF/death 1.00 0.63, 1.59 0.99
VF alone 1.05 0.65, 1.68 0.85
ENV2 Virologic suppression 0.98 0.85, 1.13 0.78
VF/off-treatment 0.99 0.79, 1.25 0.95
VF/death 1.20 0.94, 1.53 0.15
VF alone 1.31 1.02, 1.68 0.037
ENV3 Virologic suppression 1.01 0.83, 1.23 0.91
VF/off-treatment 0.86 0.65, 1.15 0.31
VF/death 1.06 0.76, 1.48 0.72
VF alone 1.15 0.80, 1.65 0.47
MEAN Virologic suppression 1.24 0.92, 1.68 0.15
VF/off-treatment 0.34 0.16, 0.72 0.005
VF/death 0.57 0.24, 1.35 0.20
VF alone 0.70 0.28, 1.76 0.46
MED Virologic suppression 1.63 1.02, 2.62 0.042
VF/off-treatment 0.31 0.15, 0.65 0.002
VF/death 0.64 0.27, 1.54 0.32
VF alone 0.76 0.29, 2.01 0.58
The table shows results from age-stratified Cox proportional hazards regression
models for the association of HIV diversity with time to virologic suppression
(defined as two consecutive HIV viral load values ,400 copies/mL) and study
endpoints, including: composite outcome of virologic failure or death (VF/
death); composite outcome of virologic failure or discontinuation of study
treatment (VF/off-treatment); and virologic failure alone (VF alone). Note that
higher POL region diversity is positively associated with a shorter time to
virologic suppression (a good clinical outcome, HR: 1.57) and is negatively
associated with a longer time to study endpoints that are bad clinical outcomes
(VF/off-treatment, HR: 0.35; VF alone, HR: 0.19; VF/death, HR: 0.16). In other
words, higher POL region diversity is associated with improved clinical outcome
for all four variables. Analyses were adjusted for study treatment regimen, age
(years), CD4 cell percentage (CD4%), and HIV viral load (,750,000 vs.
$750,000 copies/mL). HRM scores were obtained for six regions of the HIV
genome (see Methods); analyses were also performed for the mean (MEAN) and
median (MED) of all six HRM scores. Hazard ratios (HR) are shown as per unit
increase in HRM score. P values ,0.05 are bolded. Abbreviations: HR: hazard
ratio; CI: confidence intervals; VF: virologic failure.
doi:10.1371/journal.pone.0081213.t004
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sequence-based methods for diversity analysis. Those methods are
more costly and labor intensive than the HRM diversity assay and
also produce more complex data sets that may be more difficult to
analyze than single numeric HRM scores. In contrast, the HRM
diversity assay is relatively simple to perform and is well-suited for
analysis of multiple genomic regions. This makes it feasible to
perform larger studies such as this one, which evaluated six
genomic regions in 139 children (.800 measures). The major
finding in this study was that higher levels of pol region diversity
were associated with better treatment outcomes among African
children on ART. Understanding the relationship between HIV
diversity and the response to ART in HIV-infected children and
adults may provide new insights into factors that impact clinical
responses to ART.
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